Physician profile
Mark A Werner
NPI 1023033388
$23,808.39
in general payments reported to CMS, 2019-2025
26 companies · $574 in 2025
The $574 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $327 · 2021: $851 · 2022: $403 · 2023: $331 · 2024: $598 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21,146.72 | 2019-2021 | |
| Abbvie INC. | $516.23 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $465.26 | 2021-2025 | Clareon |
| Sumitomo Pharma America, INC. | $218.66 | 2023-2024 | Myfembree |
| Sight Sciences, INC. | $165.65 | 2020-2023 | Omni Surgical System |
| Dompe US, INC. | $153.68 | 2020-2025 | Oxervate |
| Allergan, INC. | $149.74 | 2019-2021 | |
| Rxsight INC | $124.93 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $115.56 | 2024 | Tecnis Iol |
| Tearlab Corp | $104.69 | 2022 | |
| Sun Pharmaceutical Industries INC. | $86.48 | 2025 | |
| Novartis Pharmaceuticals Corporation | $69.44 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $58.13 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alimera Sciences, INC. | $54.52 | 2020 | |
| Astellas Pharma US INC | $54.47 | 2023-2025 | Izervay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $50.41 | 2023-2024 | Dextenza |
| Regeneron Healthcare Solutions, INC. | $48.53 | 2020-2025 | Eylea Hd, Eylea |
| Amgen INC. | $44.06 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $35.18 | 2019-2021 | |
| Glaukos Corporation | $28.02 | 2025 | Idosetr |
| Gilead Sciences, INC. | $20.69 | 2025 | |
| New World Medical,INC. | $20.07 | 2022 | |
| Omeros Corporation | $19.89 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $19.03 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $18.95 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.